



## GeneDx to Participate in Upcoming Investor Conferences

February 25, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 25, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences:

- **TD Cowen 46th Annual Health Care Conference**

Boston, MA

Fireside Chat: Monday, March 2 at 1:50 p.m. ET

- **Barclays 28th Annual Global Healthcare Conference**

Miami Beach, FL

Presentation: Wednesday, March 11 at 3:00 p.m. ET

Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website at [ir.genedx.com/news-events/events](https://ir.genedx.com/news-events/events).

### About GeneDx

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity™ also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit [genedx.com](https://genedx.com) and connect with us on [LinkedIn](#), [Facebook](#), and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260225210999/en/): <https://www.businesswire.com/news/home/20260225210999/en/>

### Investor Relations Contact:

[Investors@GeneDx.com](mailto:Investors@GeneDx.com)

### Media Contact:

[Press@GeneDx.com](mailto:Press@GeneDx.com)

Source: GeneDx